Get the Stockscreener App
1.38
0.73%
0.010
NanoViricides Inc stock is traded at $1.38, with a volume of 154.84K.
It is up +0.73% in the last 24 hours and up +15.00% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.37
Open:
$1.36
24h Volume:
154.84K
Relative Volume:
0.58
Market Cap:
$35.22M
Revenue:
Net Income/Loss:
$-8.09M
P/E Ratio:
-3.1695
EPS:
-0.4354
Net Cash Flow:
$-7.37M
1W Performance:
+6.15%
1M Performance:
+15.00%
6M Performance:
+18.97%
1Y Performance:
-4.83%
1-Day Range:
$1.34
$1.40
1-Week Range:
$1.24
$1.40
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.38 | 35.22M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides - ACCESS Newswire
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives - The Tennessean
Form DEF 14A NANOVIRICIDES For: 8 October By Investing.com - Investing.com Nigeria
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - Corsicana Daily Sun
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - FinancialContent
NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 - Yahoo Finance
NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives - ACCESS Newswire
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
Book value per share of NanoViricides, Inc. – HAN:NV3P - TradingView
Cash flow from financing activities of NanoViricides, Inc. – HAN:NV3P - TradingView
NanoViricides, Inc. Balance Sheet – HAN:NV3P - TradingView
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - Yahoo! Finance Canada
NanoViricides, Inc. (NNVC) Files 10-K; NV-387 Enters Phase II Trials - TradingView
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials - Yahoo Finance
NanoViricides: Fiscal Q4 Earnings Snapshot - Yahoo Finance
NanoViricides: Fiscal Q4 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Q4 Earnings Snapshot - KHOU
NANOVIRICIDES, INC. FY 2026: Revenue $0 EPS ($0.41) — 10-K Summary - TradingView
Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides - ACCESS Newswire
An Ebola trial in Congo is dosing patients with a drug that dissolves in the mouth. - Stock Titan
NanoViricides, Inc. Auditor Raises 'Going Concern' Doubt - www.marketscreener.com
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides Inc. (NNVC) Key Financial Ratios – Valuation, Profitability & More - Value Research
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides - ACCESS Newswire
NanoViricides, Inc. (NNVC) Starts Phase II Trial of NV-387 for Mpox - TradingView
Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides - Yahoo Finance
Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us
Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides - Yahoo Finance
About 48% of confirmed Ebola cases in Congo have ended in death. NanoViricides' oral trial is set to start next week. - Stock Titan
Cash flow from financing activities of NanoViricides, Inc. – HAM:NV3P - TradingView
Operating cash flow per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Return on equity % of NanoViricides, Inc. – HAM:NV3P - TradingView
Gross margin % of NanoViricides, Inc. – HAM:NV3P - tradingview.com
CapEx per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Total debt per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Basic earnings per share (basic EPS) of NanoViricides, Inc. – HAM:NV3P - TradingView
NanoViricides Registers Phase II Ebola Trial for Oral Antiviral NV-387 in DRC - citybuzz.co
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - ACCESS Newswire
NanoViricides (AMEX: NNVC) May Generate Up to $4.4 Million Through Warrant Exercises - Kalkine Media
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for MeaslesEnables Priority Review Voucher - ACCESS Newswire
U.S. measles cases reach 2,903 by Aug. 27 as NanoViricides prepares a trial - Stock Titan
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - Yahoo Finance
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Pre-Revenue DevelopmentGAAP Earnings Report - careplusvn.com
NanoViricides Inc. (NNVC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
NanoViricides (NNVC) Q2 2026 Earnings: Profit Per Share Surpasses Its Benchmark in the Latest Session; Closing Reaction: The Stock Loses 4.51% for the Current SessionProfit Guidance Range - vinanet.vn
NanoViricides (NNVC) Chart: Ends Lower by 3.08% at $1.29 in the Latest Session; Technical View: the Supplied Trading Band Runs From $1.23 to $1.35 in the Available RecordFibonacci Fan - vinanet.vn
NanoViricides (NNVC) Results Breakdown: EPS Exceeds Its Estimate; After Earnings: Shares Move Higher 1.53% - careplusvn.com
NanoViricides (NNVC) Results Breakdown: EPS Exceeds Its Estimate; After Earnings: Shares Move Higher 1.53%Subscription Growth Report - dars.gov.et
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):